Genetic Testing For Hereditary Cancers

Prevents Cancer Earlier

In the history of cancer treatment, precision medicine is now endorsed as a modern and preferred way for a healthcare system to take care of its cancer patients. Challenges in identifying the right drug for every cancer patient, as new drugs are emerging for specific genomic mutations, can be tackled strategically by obtaining a cancer patient's unique cancer genomic profile. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well, as these have been commitments of the US FDA from 2018. The wave of precision medicine has also increased the approvals of companion diagnostics, which has resulted in ACT Genomics' genomic profiling service being on the waiting list for US FDA approval.


Why You Need to Know About Precision Medicine

The top global pharma companies are increasingly conducting clinical trials using precision medicine, which requires a cancer patient's genomic information through genomic profiling. This evolution has been felt by most hospitals, so it is increasingly more likely that genomic profiling will be required if you wish to try a new treatment option.


Do You Need to Prevent Cancer by Gene Testing?

To know or not to know, that is a question. Some people consider that there are no drugs for inherited genetic variants before the cancer is formed, which causes a significant mental burden; because 5-10% of cancers are caused by inherited genetic variants, if you have a family history of cancer, you are at a high risk of developing cancer. Therefore, knowing which inherited genetic variants you have may help you organize a better health management strategy. There are many inherited genetic variants known for several cancers, including BRCA1/2 genes. People carrying inherited genetic variants have a higher lifetime risk of cancer, up to 90 times higher than someone without a mutation.


More Comprehensive Diagnostic Solutions Than Traditional Hereditary Gene Testing

Through next-generation sequencing (NGS), ACTRisk™ hereditary gene testing decodes 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes, to provide more information for your health management strategy. 


Advantages from Hereditary Gene Testing

✔ More humane process: Only a small specimen is required for the simultaneous detection of 67 genes.

✔ More ideal management:  Uses genomic information for prevention measures.

Type of patients 
∙ Multiple family members who have cancer 
∙ Any individual who is concerned about the inherent risk of hereditary cancers and cancer syndromes 
∙ A family member who has multiple cancers, an early-onset cancer, or a rare cancer 

Specimen requirements

Turnaround time
12 working days*

*starting from the date of receipt of approved samples at our CAP-accredited laboratory

More Stories

ACT Genomics provides the best precision medicine service to every patient every day. Providing patients with the ideal testing experience is our goal. Below, you will find stories from real ACT Genomics patients — about their experiences. We hope these will give you more of an idea of what to expect when you have our test for your needs.

Read More